These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9152572)

  • 1. The use of claims databases for outcomes research: rationale, challenges, and strategies.
    Motheral BR; Fairman KA
    Clin Ther; 1997; 19(2):346-66. PubMed ID: 9152572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. It is important to note that RWD will never replace the more traditional and more robust RCT data; however, the emerging trend is to incorporate data that are more generalizable. Introduction.
    Mullins CD; Sanchez RJ
    J Manag Care Pharm; 2011; 17(9 Suppl A):S03-4. PubMed ID: 22074667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.
    Garrison LP; Neumann PJ; Erickson P; Marshall D; Mullins CD
    Value Health; 2007; 10(5):326-35. PubMed ID: 17888097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real world designs in economic evaluation. Bridging the gap between clinical research and policy-making.
    Baltussen R; Leidl R; Ament A
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):449-58. PubMed ID: 10662392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical clinical trials for translating research to practice: design and measurement recommendations.
    Glasgow RE; Magid DJ; Beck A; Ritzwoller D; Estabrooks PA
    Med Care; 2005 Jun; 43(6):551-7. PubMed ID: 15908849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.
    Ramsey SD; Willke RJ; Glick H; Reed SD; Augustovski F; Jonsson B; Briggs A; Sullivan SD
    Value Health; 2015 Mar; 18(2):161-72. PubMed ID: 25773551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis.
    Hawton A; Shearer J; Goodwin E; Green C
    Appl Health Econ Health Policy; 2013 Aug; 11(4):331-41. PubMed ID: 23637055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A checklist for retrospective database studies--report of the ISPOR Task Force on Retrospective Databases.
    Motheral B; Brooks J; Clark MA; Crown WH; Davey P; Hutchins D; Martin BC; Stang P
    Value Health; 2003; 6(2):90-7. PubMed ID: 12641858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy.
    Tunis SR; Stryer DB; Clancy CM
    JAMA; 2003 Sep; 290(12):1624-32. PubMed ID: 14506122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I.
    Berger ML; Mamdani M; Atkins D; Johnson ML
    Value Health; 2009; 12(8):1044-52. PubMed ID: 19793072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence-based medicine, systematic reviews, and guidelines in interventional pain management: part 6. Systematic reviews and meta-analyses of observational studies.
    Manchikanti L; Datta S; Smith HS; Hirsch JA
    Pain Physician; 2009; 12(5):819-50. PubMed ID: 19787009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trial-based cost-effectiveness analyses of antipsychotic use.
    Polsky D; Doshi JA; Bauer MS; Glick HA
    Am J Psychiatry; 2006 Dec; 163(12):2047-56. PubMed ID: 17151153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of patient-reported and economic outcomes: value to stakeholders in the decision-making process in patients with type 2 diabetes mellitus.
    Vieta A; Badia X; Sacristán JA
    Clin Ther; 2011 Sep; 33(9):1225-45. PubMed ID: 21856000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. External validity of randomised controlled trials: "to whom do the results of this trial apply?".
    Rothwell PM
    Lancet; 2005 Jan 1-7; 365(9453):82-93. PubMed ID: 15639683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.
    Coons SJ; Gwaltney CJ; Hays RD; Lundy JJ; Sloan JA; Revicki DA; Lenderking WR; Cella D; Basch E;
    Value Health; 2009 Jun; 12(4):419-29. PubMed ID: 19900250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A research roadmap for complementary and alternative medicine - what we need to know by 2020.
    Fischer F; Lewith G; Witt CM; Linde K; von Ammon K; Cardini F; Falkenberg T; Fønnebø V; Johannessen H; Reiter B; Uehleke B; Weidenhammer W; Brinkhaus B
    Forsch Komplementmed; 2014; 21(2):e1-16. PubMed ID: 24851850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of information methods to design a clinical trial in a small population to optimise a health economic utility function.
    Pearce M; Hee SW; Madan J; Posch M; Day S; Miller F; Zohar S; Stallard N
    BMC Med Res Methodol; 2018 Feb; 18(1):20. PubMed ID: 29422021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A practical guide for using registry data to inform decisions about the cost effectiveness of new cancer drugs: lessons learned from the PHAROS registry.
    Blommestein HM; Franken MG; Uyl-de Groot CA
    Pharmacoeconomics; 2015 Jun; 33(6):551-60. PubMed ID: 25644460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.